• Tues news: Prostate cancer trials to watch. Merck’s subcutaneous Keytruda. Apellis sees positive in Astellas CRL. Future of Medicare price negotiations. JNJ psoriasis results. See more on our front page

Heard Merck IT cuts (er, announcements) coming tomorrow...

















Just like corporate picks a direction - then changes it, so goes the rest of the company. We're not slashing R&D spending until we are and were done outsourcing until we're not.

Good luck.